NCT03005288 - Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

March 21, 2019

Study Completion Date

May 8, 2019

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

BYM338 10 mg/kg

intravenous infusion every four weeks

OTHER

Placebo

intravenous infusion every four weeks

Trial Locations (9)

Novartis Investigative Site, Orlando

Novartis Investigative Site, Miami Lakes

Novartis Investigative Site, Miami

Novartis Investigative Site, Miami

Novartis Investigative Site, Baton Rouge

Novartis Investigative Site, Anaheim

Novartis Investigative Site, Berlin

Novartis Investigative Site, Eatontown

Novartis Investigative Site, Merthyr Tydfil